Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
Open Access
- 28 April 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Biomedical Science
- Vol. 17 (1), 32
- https://doi.org/10.1186/1423-0127-17-32
Abstract
Background There is an urgent need to develop new innovative therapies for the control of advanced cancer. The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer. Methods In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 (HPV-16) E7 antigen (CRT/E7) with the TLR7 agonist imiquimod for their ability to generate E7-specific immune responses and antitumor effects in tumor-bearing mice. Results We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to an enhancement in the E7-specific CD8+ T cell immune responses and a decrease in the number of myeloid-derived suppressor cells in the tumor microenvironment of tumor-bearing mice. Furthermore, treatment with CRT/E7 DNA in combination with imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice. In addition, treatment with imiquimod led to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment. Macrophages and NK1.1+ cells were found to play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod. Conclusions Thus, our data suggests that the combination of therapeutic HPV DNA vaccination with topical treatment with the TLR7 agonist imiquimod enhances the antitumor immunity induced by DNA vaccination. The current study has significant implications for future clinical translation.Keywords
This publication has 31 references indexed in Scilit:
- Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasiaBritish Journal of Cancer, 2010
- HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell ResponsesClinical Cancer Research, 2009
- Myeloid-Derived Suppressor Cells: Linking Inflammation and CancerPublished by The American Association of Immunologists ,2009
- A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3Clinical Cancer Research, 2008
- Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cellsImmunological Reviews, 2008
- Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cellsExpert Review of Vaccines, 2007
- Comparison of HPV DNA vaccines employing intracellular targeting strategiesGene Therapy, 2004
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002
- Review Article Imiquimod applied topically: a novel immune response modifier and new class of drugInternational Journal of Immunopharmacology, 1999
- DNA vaccinesLife Sciences, 1996